MEDICAL UPDATE: AZT/DDC Combination Study

MEDICAL UPDATE: AZT/DDC Combination Study

Being Alive Newsletter, Being Alive/Los Angeles - March 1992
presented by Mark Katz MD and reported by Jim Stoecker

The results of the earliest major study of combination antiviral therapy, ACTG 106, have now been published in the Annals of Internal Medicine. As we have reported in the past, this study showed that daily combined doses of 300-600 mg of AZT and 1-2 mg of ddC resulted in a higher rise in T-cells and a more prolonged rise than that from daily AZT alone. No significant toxicities were reported.

This study was very small; only 56 patients were included. Now a much larger study is underway. There seems little doubt that combination antiviral therapy is an idea whose time has come.
920301
BA920302

AEGiS is made possible through unrestricted grants from Roxane Laboratories, the National Library of Medicine, and donations from users like you. Always watch for outdated information. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1992 - Beings Alive. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. Being Alive, 621 N. San Vicente Blvd., West Hollywood, CA 90069, Tel - 310.289.2551; FAX - 310.289.9866; Email: BeiAlive@aol.com http://www.beingalivela.org/

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1992. AEGIS.